SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with profound metabolic rewiring and resistance to therapy. This dual effect led to autophagic flux blockade, resulting in excessive ROS accumulation, mitochondrial dysfunction, and apoptosis.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with profound metabolic rewiring and resistance to therapy. This dual effect led to autophagic flux blockade, resulting in excessive ROS accumulation, mitochondrial dysfunction, and apoptosis.
What the study was
- Study design
- Preclinical study
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Cellular oncology (Dordrecht, Netherlands)
Why it surfaced
Relevant Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.